Bacteriological and clinical studies on meropenem

Yoshiro Sawae, Nobuyuki Shimono, Hiroyasu Misumi, Katsuhiko Eguchi, Atsushi Takita, Kazuyuki Higuchi, Kaoru Okada, Masahide Takii, Michio Fukuma, Kiyoshi Ninomiya, Tsukasa Oshima, Ikuo Sumita, Takatoshi Inoue, Yukio Kumagai, Toshiyuki Ishimaru

Research output: Contribution to journalArticle

Abstract

We performed bacteriological and clinical studies on meropenem (MEPM), a new parenteral carbapenem antibiotic, with the following results. 1. Antibacterial activity The MICs of MEPM against various clinical isolates were detemined with an inoculum size of 106 cell/ml. The MIC90 was 6.25 µg/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, ≦0.05 for Escherichia coli, 0.1 for Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris, 1.56 for Enterobacter cloacae, 3.13 for Enterobacter aerogenes, 0.39 for Serratia marcescens, 0.78 for Citrobacter freundii and, 50 for Pseudomonas aeruginosa. Its activity against gram-positive cocci was less than that of imipenem (IPM), but against gram-negative rods other than P. aeruginosa its activity was more potent than IPM, ceftazidime (CAZ) cefoperazone (CPZ), and piperacillin (PIPC). Its activity against P. aeruginosa was the same as that of IPM and CAZ, but more active than CPZ and PIPC.

Original languageEnglish
Pages (from-to)401-411
Number of pages11
JournalCHEMOTHERAPY
Volume40
DOIs
Publication statusPublished - Jan 1 1992

Fingerprint

meropenem
Imipenem
Pseudomonas aeruginosa
Cefoperazone
Piperacillin
Ceftazidime
Citrobacter freundii
Proteus vulgaris
Enterobacter aerogenes
Enterobacter cloacae
Gram-Positive Cocci
Proteus mirabilis
Serratia marcescens
Carbapenems
Enterococcus faecalis
Klebsiella pneumoniae
Cell Size
Staphylococcus aureus
Escherichia coli
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Sawae, Y., Shimono, N., Misumi, H., Eguchi, K., Takita, A., Higuchi, K., ... Ishimaru, T. (1992). Bacteriological and clinical studies on meropenem. CHEMOTHERAPY, 40, 401-411. https://doi.org/10.11250/chemotherapy1953.40.Supplement1_401

Bacteriological and clinical studies on meropenem. / Sawae, Yoshiro; Shimono, Nobuyuki; Misumi, Hiroyasu; Eguchi, Katsuhiko; Takita, Atsushi; Higuchi, Kazuyuki; Okada, Kaoru; Takii, Masahide; Fukuma, Michio; Ninomiya, Kiyoshi; Oshima, Tsukasa; Sumita, Ikuo; Inoue, Takatoshi; Kumagai, Yukio; Ishimaru, Toshiyuki.

In: CHEMOTHERAPY, Vol. 40, 01.01.1992, p. 401-411.

Research output: Contribution to journalArticle

Sawae, Y, Shimono, N, Misumi, H, Eguchi, K, Takita, A, Higuchi, K, Okada, K, Takii, M, Fukuma, M, Ninomiya, K, Oshima, T, Sumita, I, Inoue, T, Kumagai, Y & Ishimaru, T 1992, 'Bacteriological and clinical studies on meropenem', CHEMOTHERAPY, vol. 40, pp. 401-411. https://doi.org/10.11250/chemotherapy1953.40.Supplement1_401
Sawae, Yoshiro ; Shimono, Nobuyuki ; Misumi, Hiroyasu ; Eguchi, Katsuhiko ; Takita, Atsushi ; Higuchi, Kazuyuki ; Okada, Kaoru ; Takii, Masahide ; Fukuma, Michio ; Ninomiya, Kiyoshi ; Oshima, Tsukasa ; Sumita, Ikuo ; Inoue, Takatoshi ; Kumagai, Yukio ; Ishimaru, Toshiyuki. / Bacteriological and clinical studies on meropenem. In: CHEMOTHERAPY. 1992 ; Vol. 40. pp. 401-411.
@article{04821b0237d64d96833e31881cd4c58b,
title = "Bacteriological and clinical studies on meropenem",
abstract = "We performed bacteriological and clinical studies on meropenem (MEPM), a new parenteral carbapenem antibiotic, with the following results. 1. Antibacterial activity The MICs of MEPM against various clinical isolates were detemined with an inoculum size of 106 cell/ml. The MIC90 was 6.25 µg/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, ≦0.05 for Escherichia coli, 0.1 for Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris, 1.56 for Enterobacter cloacae, 3.13 for Enterobacter aerogenes, 0.39 for Serratia marcescens, 0.78 for Citrobacter freundii and, 50 for Pseudomonas aeruginosa. Its activity against gram-positive cocci was less than that of imipenem (IPM), but against gram-negative rods other than P. aeruginosa its activity was more potent than IPM, ceftazidime (CAZ) cefoperazone (CPZ), and piperacillin (PIPC). Its activity against P. aeruginosa was the same as that of IPM and CAZ, but more active than CPZ and PIPC.",
author = "Yoshiro Sawae and Nobuyuki Shimono and Hiroyasu Misumi and Katsuhiko Eguchi and Atsushi Takita and Kazuyuki Higuchi and Kaoru Okada and Masahide Takii and Michio Fukuma and Kiyoshi Ninomiya and Tsukasa Oshima and Ikuo Sumita and Takatoshi Inoue and Yukio Kumagai and Toshiyuki Ishimaru",
year = "1992",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.40.Supplement1_401",
language = "English",
volume = "40",
pages = "401--411",
journal = "CHEMOTHERAPY",
issn = "0009-3165",

}

TY - JOUR

T1 - Bacteriological and clinical studies on meropenem

AU - Sawae, Yoshiro

AU - Shimono, Nobuyuki

AU - Misumi, Hiroyasu

AU - Eguchi, Katsuhiko

AU - Takita, Atsushi

AU - Higuchi, Kazuyuki

AU - Okada, Kaoru

AU - Takii, Masahide

AU - Fukuma, Michio

AU - Ninomiya, Kiyoshi

AU - Oshima, Tsukasa

AU - Sumita, Ikuo

AU - Inoue, Takatoshi

AU - Kumagai, Yukio

AU - Ishimaru, Toshiyuki

PY - 1992/1/1

Y1 - 1992/1/1

N2 - We performed bacteriological and clinical studies on meropenem (MEPM), a new parenteral carbapenem antibiotic, with the following results. 1. Antibacterial activity The MICs of MEPM against various clinical isolates were detemined with an inoculum size of 106 cell/ml. The MIC90 was 6.25 µg/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, ≦0.05 for Escherichia coli, 0.1 for Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris, 1.56 for Enterobacter cloacae, 3.13 for Enterobacter aerogenes, 0.39 for Serratia marcescens, 0.78 for Citrobacter freundii and, 50 for Pseudomonas aeruginosa. Its activity against gram-positive cocci was less than that of imipenem (IPM), but against gram-negative rods other than P. aeruginosa its activity was more potent than IPM, ceftazidime (CAZ) cefoperazone (CPZ), and piperacillin (PIPC). Its activity against P. aeruginosa was the same as that of IPM and CAZ, but more active than CPZ and PIPC.

AB - We performed bacteriological and clinical studies on meropenem (MEPM), a new parenteral carbapenem antibiotic, with the following results. 1. Antibacterial activity The MICs of MEPM against various clinical isolates were detemined with an inoculum size of 106 cell/ml. The MIC90 was 6.25 µg/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, ≦0.05 for Escherichia coli, 0.1 for Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris, 1.56 for Enterobacter cloacae, 3.13 for Enterobacter aerogenes, 0.39 for Serratia marcescens, 0.78 for Citrobacter freundii and, 50 for Pseudomonas aeruginosa. Its activity against gram-positive cocci was less than that of imipenem (IPM), but against gram-negative rods other than P. aeruginosa its activity was more potent than IPM, ceftazidime (CAZ) cefoperazone (CPZ), and piperacillin (PIPC). Its activity against P. aeruginosa was the same as that of IPM and CAZ, but more active than CPZ and PIPC.

UR - http://www.scopus.com/inward/record.url?scp=0026750765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026750765&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.Supplement1_401

DO - 10.11250/chemotherapy1953.40.Supplement1_401

M3 - Article

VL - 40

SP - 401

EP - 411

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -